Telix Pharmaceuticals Revenue

In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth.

Revenue (ttm)

$803.79M

Revenue Growth

+55.61%

P/S Ratio

3.70

Revenue / Employee

$678,880

Employees

1,184

Market Cap

2.97B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	803.79M	287.24M	55.61%
Dec 31, 2024	516.55M	183.57M	55.13%
Dec 31, 2023	332.98M	224.03M	205.64%
Dec 31, 2022	108.95M	103.42M	1,873.24%
Dec 31, 2021	5.52M	1.51M	37.53%
Dec 31, 2020	4.01M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Legend Biotech	1.03B
Catalyst Pharmaceuticals	588.99M
ADMA Biologics	510.17M
IDEAYA Biosciences	218.71M
Viridian Therapeutics	70.85M
Alumis	24.05M

Revenue Rankings

TLX News

5 days ago - Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S. - GlobeNewsWire
7 days ago - Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript - Seeking Alpha
8 days ago - Telix Resubmits NDA For Brain Cancer Imaging Candidate TLX101-Px To FDA - Nasdaq
9 days ago - Telix Resubmits TLX101-Px NDA To FDA For Brain Cancer Imaging Agent - Nasdaq
9 days ago - Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate - GlobeNewsWire
14 days ago - Why Is Telix Pharmaceuticals Stock Gaining Tuesday? - Benzinga
15 days ago - Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript - Seeking Alpha
15 days ago - ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives - GlobeNewsWire

More News